

Portal Vein Embolization: My Top 5 Technical Pearls

Alban Denys

Chairman of Radiology

CHUV University of Lausanne


Disclosure

Consultant for: Terumo, Cook, Neuwave


Brand names are included in this presentation for participant clarification purposes only. No product promotion should be inferred.

Pearl 1 :access route tips and tricks....


- Indications for both exists
 - Contralat mandatory in case of Klatskin tumors
 - Ipsi depending on the embolic material






| | Controlateral route | Ipsiateral route |
|------|---|--|
| pros | Catheterism easier Final control easier Dose reduction ? Use of glue | No risk for FRL Easy puncture Access to segt 4 branches |
| Cons | Risk of complications of FRL (increased by PH) | Catherism more complex Use of glue more tricky Final control hard to achieve |




Klatskin IIIA
Left lobe volumetry: FRL 18%
Need for left lobe drainage, right PVE +LVD










Pearl 2 combine PVE and PCBD in the same procedure

Perform PVE and biliary drainage in the same procedure



Cardiovasc Intervent Radiol (2014) 37:698–704
DOI 10.1007/s00270-013-0699-7

C RSE

CLINICAL INVESTIGATION INTERVENTIONAL ONCOLOGY

cio

Simultaneous Biliary Drainage and Portal Vein Embolization Before Extended Hepatectomy for Hilar Cholangiocarcinoma: Preliminary Experience

Boris Guu · Pierre Bize · Nicolas Demartines · Mickaël Lesurtel · Alban Denys

Klatskin tumor: why should liver preparation be faster?

- 494 pats treated for biliary cancer received PVE
 - Mean delay diagnosis and surgery unknown
 - But 2 steps strategy biliary then PVE
 - 24.7% did not receive resection due to tumor progression.....
 - More frequent in gallbladder cancer than with klatskin tumor

[Dig Surg](#). 2012;29(1):23-9. doi: 10.1159/000335718. Epub 2012 Mar 15.


Portal vein embolization before extended hepatectomy for biliary cancer: current technique and review of 494 consecutive embolizations.

[Ebata T](#)¹, [Yokoyama Y](#), [Igami T](#), [Sugawara G](#), [Takahashi Y](#), [Nagino M](#).

Delay between tertiary center consultation and treatment is 74 days in amsterdam series (Rhuys AT HPB 2014)
Delay from biliary decompression to PVE in US series between 55 to 61 days followed (Walter T JVIR 2013)

Pearl 3 Use a mixture of Glue and Lipiodol

- Try first the most tricky portal branches close to the portal bifurcation and move to the easy ones
- Dilute one to 2 in the first injections to embolize distally and then 1 to 1 finally




Why Glue?

| | NBCA | Microparticles+coils | <i>P value</i> |
|----------------------|------------|----------------------|----------------|
| Age | 68±12 | 67±9 | >.05 |
| Sex ratio (W/M) | 5/9 | 4/10 | >.05 |
| Cirrhosis/metastases | 5/9 | 5/8 | >.05 |
| Total liver volume | 1978±1352 | 1692±391 | >.05 |
| Left lobe volume | 470±210 | 495±191 | >.05 |
| FRL ratio | 0.027±0.11 | 0.29±0.06 | >.05 |

Much less contrast for Glue than coils and particles (164 vs 262)
Similar rate of complications
Lower cost (Europe)

Guiu, Denys et al CVIR 2013



Pearl 4 : Prepare your table with G5% NO SALINE.....



Pearl 5: embolize the hepatic veins as well....

Eur Radiol. 2017 Aug;27(8):3343-3352. doi: 10.1007/s00330-017-4744-9. Epub 2017 Jan 18.

Extended liver venous deprivation before major hepatectomy induces marked and very rapid increase in future liver remnant function.

Guiu B^{1,2,3}, Quenet F⁴, Escal L⁵, Bibeau F⁶, Piron L⁵, Rouanet P⁴, Fabre JM⁷, Jacquet E⁸, Denys A⁹, Kotzki PO^{10,11}, Verzilli D¹², Deshayes E^{10,11}.

Initial experience with patients candidate to resection with FRL <25% or FRL function <2.69%/min/m² at mebrofin scintigraphy (VanGulik criteria)

PVE + Right AND middle hepatic vein simultaneous embolization

Etiology: 8 liver mets CRC (, Klatskin 1, GB carcinoma 1)

Results:

FRL function increased by 64% (range 28-107%) at day 21


Maximal liver function gain was at day 7 (+65+/-16%)

Maximal FRL volume increased by 53% at 7 days (25+/-8 days a week)

Opens the gate for earlier resection between 1 and 2 week

Comparison to PVE

- 1 randomized trial starting in France in 2019
- Lausanne experience 6 years



Liver venous deprivation compared to portal vein embolization to induce hypertrophy of the future liver remnant before major hepatectomy: A single center experience

Kosuke Kobayashi, MD^a, Takamune Yamaguchi, MD^a, Alban Denys, MD^b, Lindsay Perron, MD^b, Nermin Halkic, MD^a, Nicolas Demartines, MD^{a,*}, Emmanuel Melloul, MD^a

^a Department of Visceral Surgery, Lausanne University Hospital and University of Lausanne, Switzerland
^b Interventional Radiology, Lausanne University Hospital and University of Lausanne, Switzerland

Table 1. Patients' characteristics

| Variables | HVE and PVE (n=18) | PVE (n=30) | p value |
|---|-----------------------|-------------------|---------|
| Age, year | 66 (31-85) | 64 (41-75) | 0.975 |
| Sex, male : female | 10 : 8 | 19 : 11 | 0.594 |
| BMI, kg/m ² | 23.4 (18.9-35.6) | 23.8 (17.1-32.5) | 0.624 |
| Total bilirubin, μmol/dl | 6.5 (3-348) | 10 (3-62) | 0.499 |
| PT, % | 100 (65-150) | 100 (60-120) | 0.081 |
| AST, U/l | 36 (18-189) | 46 (14-217) | 0.390 |
| ALT, U/l | 41 (15-241) | 45 (12-522) | 0.644 |
| Preoperative drainage of bile duct ERCP / percutaneous | 6 (33.3%) 2 / 4 | 2 (6.7%) 1 / 1 | 0.016 |
| Embolization | | | |
| RPV + P4/ RPV | 1 / 17 | 3 / 27 | |
| RHV / RHV and MHV | 13 / 2 | - | - |
| Diagnosis | | | |
| Colorectal metastasis | 9 (50.0%) | 26 (86.7%) | 0.006 |
| Hepatocellular carcinoma | 2 (11.1%) | 2 (6.7%) | 0.590 |
| Cholangiocarcinoma (K IIIa) | 7 (38.9%) | 2 (6.7%) | 0.006 |

Table 3. Volumetric analysis and outcome

| Variables | HVE and PVE n=18 | PVE n=30 | p value |
|--|----------------------------|---------------------------|--------------|
| Volumetric analysis of pre-operation | | | |
| TLV, ml | 1592 (1203-2328) | 1650 (959-2605) | 0.831 |
| SLV, ml | 1278 (1007-1520) | 1281 (1071-1557) | 0.865 |
| FRL volume, ml | 530 (334-989) | 523 (288-1032) | 0.774 |
| FRL / TLV, % | 34.3 (24.4-44.6) | 32.9 (17.4-58.3) | 0.749 |
| FRL / SLV, % | 39.4 (25.5-65.1) | 38.9 (24.9-96.3) | 0.949 |
| Spleen volume | 206 (82-401) | 211 (70-451) | 0.932 |
| Volumetric outcome of post-embolization | | | |
| Days between embolization and CT, days | 23 (13-35) | 26 (15-72) | 0.277 |
| TLV, ml | 1859 (1373-2424) | 1620 (1014-2314) | 0.045 |
| FRL volume, ml | 721 (555-1186) | 696 (317-1086) | 0.360 |
| FRL / TLV, % | 42.7 (30.1-55.8) | 43.0 (30.4-71.4) | 0.733 |
| FRL / SLV, % | 58.1 (42.0-78.0) | 51.3 (29.1-101.4) | 0.131 |
| Spleen volume, ml | 257 (89-449) | 207 (78-521) | 0.418 |
| Post-TLV – Pre-TLV, ml | 128 (-92-585) | 12 (-337-439) | 0.002 |
| Post-FRL volume – Pre-FRL volume, ml | 195 (80-442) | 109 (11-463) | 0.009 |
| Post-FRL% / Pre-FRL% of TLV, % | 121.0 (108.3-216.3) | 122.9 (97.6-202.8) | 0.966 |
| Post-FRL% / Pre-FRL% of SLV, % | 134.7 (112.0-232.3) | 124.3 (98.4-203.4) | 0.039 |
| Post-Spleen / Pre-Spleen, % | 123.1 (96.2-173.3) | 110.3 (45.0-181.0) | 0.048 |

Data are presented as median (range) or n (%).
Abbreviations: TLV, total liver volume; SLV, standard liver volume; FRL, future remnant liver

Doubling of the FLR vs PVE
Increase in spleen size

| Variables | HVE and PVE (n=18) | PVE (n=30) | p value |
|---|-----------------------|-----------------|---------|
| Intraoperative outcomes | | | |
| Days between embolization and operation, days | 36 (23-109) | 35 (20-181) | 0.924 |
| Right Hepatectomy | 8 (44.4%) | 19 (63.3%) | 0.202 |
| Extended Right Hepatectomy | 10 (55.6%) | 11 (36.7%) | 0.202 |
| Operative time, min | 363 (274-577) | 344 (210-554) | 0.198 |
| Estimated blood loss, ml | 850 (600-2500) | 1000 (200-2600) | 0.716 |
| Pringle maneuver | 18 (100%) | 29 (97.0%) | 0.434 |
| Postoperative morbidity | | | |
| Morbidity | 11 (61.1%) | 15 (50.0%) | 0.455 |
| Clavien-Dindo classification I or II | 4 (22.2%) | 6 (20.0%) | 0.854 |
| Clavien-Dindo classification > III | 7 (38.9%) | 11 (30.0%) | 0.527 |
| Comprehensive Complication Index | 16.6 (0-100) | 4.4 (0-57) | 0.364 |
| Mortality | 0 | 0 | |
| Postoperative length of stay, days | 14 (6-57) | 11 (5-69) | 0.086 |
| Data are presented as median (range) or n (%). Abbreviations: BMI, body mass index; PT, prothrombin time; AST, aspartate aminotransferase; ALT, alanine aminotransferase | | | |

No difference in blood loss despite the »Budd-Chiari « effect
No difference in operative outcome despite more extended right hepatectomies

série : Abdomen 21s-75%

@ (TOUT) >

8

examen : ANGIO. ILIAQUE

série : Abdomen 21s-75%

12 (TOUT) >

14-02

16:29

80

78% P

DFOV 30.0 x 29.3 c

Visionne

5 c

VO / 0.00 CRA

CIO



Embark in EuroLVD adventure

IEUROILVD

Home

About

Literature

Contact Us

login

Welcome to IEUROILVD website.

EuroLVD.net is a platform for simultaneous Liver venous deprivation technique that has been developed to enhance liver hypertrophy before a major hepatectomy.

Preliminary data have demonstrated its safety and efficiency compared to standard portal vein embolization (Kobayashi et Al., Surgery 2020).

This platform provides the link to the EuroLVD registry as well as ongoing RCTs on this topic.

to participate to the EuroLVD registry

REGISTER HERE

Under the umbrella of EHPBA, contact: emmanuel-melloul@chuv.ch; alban.denys@chuv.ch